Niraparib for mesothelioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Jul 2017: Trial registered, NCT03207347
  2. 13 Aug 2018: Trial started, NCT03207347

The trials

NCT03207347: A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

State
Completed
Phase
Phase 2
People
37 taking part
Started
13 Aug 2018
Primary completion
30 Aug 2022
Arms
Cohort A, Cohort B
Results
Posted on the registry
Papers
doi:10.1200/po-24-00406
  1. 2 Jul 2017: Trial registered
  2. 13 Aug 2018: Trial started
  3. 30 Aug 2022: Trial completed
  4. 15 Sep 2023: Trial results posted

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.